Clinical Trial Update: A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis [Phase 2]

View source ↗

Summary

Phase II study assessing efficacy and safety of AUR101 in moderate-to-severe chronic plaque-type psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque-type Psoriasis

Drugs mentioned

• AUR101

Snippet

Sponsor: Aurigene Discovery Technologies Limited | Conditions: Chronic Plaque-type Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2023-08-14